2024
The effect of acute estrogen suppression on cutaneous endothelium-dependent vasodilation in women with endometriosis
Colburn A, Leone C, Alexander L, Stachenfeld N. The effect of acute estrogen suppression on cutaneous endothelium-dependent vasodilation in women with endometriosis. Physiology 2024, 39: 421. DOI: 10.1152/physiol.2024.39.s1.421.Peer-Reviewed Original ResearchEndothelium-dependent vasodilationEstrogen suppressionHealthy controlsLDF/mean arterial pressureSodium nitroprusside perfusionDose-response curveLaser Doppler flowmetryCardiovascular disease riskCutaneous vascular conductanceACh doseEndometriosis patientsPerfusion of acetylcholineMenstrual cycleIntradermal microdialysisSuppress estrogenEndothelial functionArterial pressureEndometriosisVasodilatory functionDoppler flowmetryVascular conductanceVasodilationMaximal vasodilationGraded perfusionEstrogenNeoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Ríos-Hoyo A, Cobain E, Huppert L, Beitsch P, Buchholz T, Esserman L, van 't Veer L, Rugo H, Pusztai L. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer. Journal Of Clinical Oncology 2024, 42: 2632-2636. PMID: 38593393, DOI: 10.1200/jco.23.02614.Peer-Reviewed Original ResearchProgranulin deficiency associates with postmenopausal osteoporosis via increasing ubiquitination of estrogen receptor α
Li G, Wang A, Tang W, Fu W, Tian Q, Jian J, Lata M, Hettinghouse A, Ding Y, Wei J, Zhao X, Wang M, Dong Q, Liu C, Xu Y. Progranulin deficiency associates with postmenopausal osteoporosis via increasing ubiquitination of estrogen receptor α. Genes & Diseases 2024, 12: 101221. PMID: 39559258, PMCID: PMC11570241, DOI: 10.1016/j.gendis.2024.101221.Peer-Reviewed Original ResearchPostmenopausal osteoporosisEstrogen receptorReceptor AEstrogen signalingTreatment of postmenopausal osteoporosisOvariectomy-induced bone lossEstrogen-mediated inhibitionRegulation of bone mineral densityBone mineral densityEstrogen receptor aPGRN-deficient miceInhibition of osteoclastogenesisPostmenopausal womenEstrogen deficiencyMineral densityLoss of progranulinEstrogen regulationBone lossBone massPositive feedback regulatory loopBone resorptionOsteoporosisTherapeutic approachesEstrogenOsteoporosis model
2023
Effect of Hormones and Biogenic Amines on Growth and Survival of Enterococcus durans
El’-Registan G, Zemskova O, Galuza O, Ulanova R, Il’icheva E, Gannesen A, Nikolaev Y. Effect of Hormones and Biogenic Amines on Growth and Survival of Enterococcus durans. Microbiology 2023, 92: 517-533. DOI: 10.1134/s0026261723600866.Peer-Reviewed Original ResearchPersister formationDose-dependent stimulationNatriuretic peptideDormant formsStationary growth phaseBrain natriuretic peptideAtrial natriuretic peptidePersister cellsHuman microbiomeAcid bacteriaUncultured onesBiofilm formationLab culturesMonths of incubationBacterial growthGrowth phaseDose-dependent extensionDormancy depthBiofilm growthRegulatory systemEffects of hormonesEstrogenHormonePeptideTested hormones
2022
A computational lens on menopause-associated psychosis
Fisher VL, Ortiz LS, Powers AR. A computational lens on menopause-associated psychosis. Frontiers In Psychiatry 2022, 13: 906796. PMID: 35990063, PMCID: PMC9381820, DOI: 10.3389/fpsyt.2022.906796.Peer-Reviewed Original ResearchEstrogen declinePsychotic symptomsNew-onset psychosisPathogenesis of psychosisPsychotic episodeNeural pathwaysSymptom presentationAge groupsImpair functioningProtective factorsPsychosisRisk periodSymptomsPatient-specific pathwaysDisease statesEarly adulthoodBiological correlatesNeural mechanismsEstrogenSex differencesEpisodesLatent stateExtreme distressMenopausePathogenesisContinuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis.
Badreddine J, Lee M, Mishra K, Pope R, Kim J, Hong S, Gupta S, Song J, Shin J, Ghayda R. Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis. European Review For Medical And Pharmacological Sciences 2022, 26: 2511-2517. PMID: 35442466, DOI: 10.26355/eurrev_202204_28488.Peer-Reviewed Original ResearchConceptsVenous thromboembolic eventsMale-to-female gender affirmation surgeryRisk of venous thromboembolic eventsEstrogen therapyGender-affirming surgeryThromboembolic eventsMeta-analysisContinuous estrogen therapyUsage of estrogenIncreased VTE riskCochrane Library databasesSystematic reviewProspective studyVTE riskLibrary databasesOdds ratioTherapyEstrogenTransgender patientsVaginoplastySurgeryPatientsRiskMaleEMBASEChapter 11 Hormonal control of growth
Holt E, Lupsa B, Lee G, Bassyouni H, Peery H. Chapter 11 Hormonal control of growth. 2022, 335-379. DOI: 10.1016/b978-0-12-815844-9.00011-7.ChaptersChapter 4 The adrenal glands
Holt E, Lupsa B, Lee G, Bassyouni H, Peery H. Chapter 4 The adrenal glands. 2022, 101-143. DOI: 10.1016/b978-0-12-815844-9.00004-x.Chapters
2021
Sex Differences and the Role of Sex Hormones in Pulmonary Hypertension
Oakland HT, Joseph P. Sex Differences and the Role of Sex Hormones in Pulmonary Hypertension. Clinics In Chest Medicine 2021, 42: 457-465. PMID: 34353451, DOI: 10.1016/j.ccm.2021.04.006.ChaptersConceptsPulmonary hypertensionProgressive pulmonary vascular remodelingRight heart failurePulmonary arterial hypertensionPulmonary vascular remodelingSex differencesArterial hypertensionHeart failureFemale sexSex hormonesVascular remodelingHypertensionFuture treatmentBeneficial effectsEventual developmentMultiple mechanismsVasoconstrictionEarlier descriptionsInflammationPathophysiologyEstrogenPrevalenceDiseaseHormoneKRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery
Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander R, Plaxe S, Parker B, Stites E, Kurzrock R. KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. The Oncologist 2021, 26: e530-e536. PMID: 33528846, PMCID: PMC8018312, DOI: 10.1002/onco.13702.Peer-Reviewed Original ResearchConceptsMEK inhibitorsMechanism of actionOvarian cancerAromatase inhibitorsEstrogen modulationKRAS-mutantLow-grade serous ovarian cancerCombination of trametinibEstrogen receptor-positiveSerous ovarian cancerPrecision medicine strategiesPI3K inhibitorsReceptor-positiveCombination therapyEstrogen depletionTamoxifenTrametinibAgonist effectsIn vitro investigationLetrozoleEstrogenIn vitro experimentsMedicine strategiesMEKExceptional response
2020
3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Jacot W, Savage H, Dent S, Cortés J, Im Y, Dieras V, Harbeck N, Krop I, Chen J, Sokol E, Schimmoller F, Hsu J, De Laurentiis M, Wilson T. 3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer. Annals Of Oncology 2020, 31: s16. DOI: 10.1016/j.annonc.2020.03.139.Peer-Reviewed Original Research
2019
Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital
Lazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. Journal Of Anesthesia 2019, 34: 294-297. PMID: 31865457, PMCID: PMC8496978, DOI: 10.1007/s00540-019-02725-2.Peer-Reviewed Original ResearchConceptsHormonal contraceptionDrug-drug interactionsUnintended pregnancyPost-operative counselingRetrospective chart reviewChart reviewRisk patientsHormonal contraceptivesColorado HospitalAcademic hospitalFDA labelContraceptive methodsSugammadexContraceptionPatientsWomenUnnecessary riskPregnancyHospitalCounselingExposureMedicationsContraceptivesProgestinsEstrogenEndometriosis
Flores V, Taylor H. Endometriosis. DeckerMed Family Medicine 2019 DOI: 10.2310/fm.1005.Peer-Reviewed Original ResearchPelvic painSurgical therapyGrowth of endometriosisReproductive-age womenRole of estrogenDiagnosis of endometriosisGynecologic diseaseRetrograde menstruationCommon symptomsEndometriosis managementTreatment optionsPatient preferencesAge womenEndometriosisMolecular pathwaysPainPatientsAberrant gene expressionInfertilityTherapyDiseaseGene expressionDyspareuniaEstrogenEtiologyEndometriosis
Flores V, Taylor H. Endometriosis. DeckerMed Medicine 2019 DOI: 10.2310/im.1005.Peer-Reviewed Original ResearchPelvic painSurgical therapyGrowth of endometriosisReproductive-age womenRole of estrogenDiagnosis of endometriosisGynecologic diseaseRetrograde menstruationCommon symptomsEndometriosis managementTreatment optionsPatient preferencesAge womenEndometriosisMolecular pathwaysPainPatientsAberrant gene expressionInfertilityTherapyDiseaseGene expressionDyspareuniaEstrogenEtiology
2018
Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects
Diano S, Horvath TL, Mor G, Register T, Adams M, Harada N, Naftolin F. Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause The Journal Of The North American Menopause Society 2018, 25: 1201-1207. PMID: 30358714, DOI: 10.1097/gme.0000000000001219.Peer-Reviewed Original ResearchConceptsCoronary arteryEstrogen receptor immunoreactivityAmount of atherosclerosisHuman placental estrogen synthetaseHuman subjectsSmooth muscle cellsPrecursor androgensReceptor immunoreactivityCardioprotective effectsCoronary circulationEstrogen formationEstrogen receptorArteryCardiovascular systemER αMuscle cellsEndothelial cellsEstrogenEstrogen synthetaseMonkeysFirst evidenceSubjectsCellsAtherosclerosisLocal regulationBazedoxifene–Conjugated Estrogens for Treating Endometriosis
Flores VA, Stachenfeld NS, Taylor HS. Bazedoxifene–Conjugated Estrogens for Treating Endometriosis. Obstetrics And Gynecology 2018, 132: 475-477. PMID: 29995747, DOI: 10.1097/aog.0000000000002739.Peer-Reviewed Original ResearchConceptsConjugated estrogensPelvic painTreatment optionsStage III endometriosisCyclic pelvic painFirst-line therapyReproductive-aged womenPotential treatment optionManagement of dysmenorrheaUnfavorable side effectsEndometriotic lesionsGynecologic disordersHormonal agentsMenopausal symptomsOvarian parametersSide effectsAnimal studiesEndometriosisEstrogenBazedoxifenePainEffective alternativeFailure rateAbnormal effectsDysmenorrhea
2017
Thyroid hormone- and estrogen receptor interactions with natural ligands and endocrine disruptors in the cerebellum
Zsarnovszky A, Kiss D, Jocsak G, Nemeth G, Toth I, Horvath TL. Thyroid hormone- and estrogen receptor interactions with natural ligands and endocrine disruptors in the cerebellum. Frontiers In Neuroendocrinology 2017, 48: 23-36. PMID: 28987779, DOI: 10.1016/j.yfrne.2017.10.001.Peer-Reviewed Original ResearchConceptsEffects of phytoestrogensThyroid hormonesBrain functionNormal physiological settingsMetabolic parametersMature brainEstrogen receptor interactionSteroid hormonesBrain developmentHormoneHomeostatic parametersIntercellular actionsHormonal mechanismsReceptor interactionNatural ligandEnergy metabolismCerebellumEndocrine disruptorsPhytoestrogensPivotal rolePhysiological settingsMetabolismGliaEstrogenNeuronsSafety and benefit considerations for menopausal hormone therapy
Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS. Safety and benefit considerations for menopausal hormone therapy. Expert Opinion On Drug Safety 2017, 16: 941-954. PMID: 28664754, DOI: 10.1080/14740338.2017.1343298.Peer-Reviewed Original ResearchConceptsSafety of HTConjugated equine estrogensHormone therapyEquine estrogensHealth initiativesDifferent estrogensEstrogen-progestogen therapyMenopausal hormone therapyUnexpected safety concernsWomen's Health InitiativeRoute of administrationHT initiationEffect of ageSafety profileDifferent progestogensCardiovascular diseaseObservational studySynthetic progestinsAdministration routeEstrogenTherapyClinical useSafety evidenceRegimensFurther studies
2016
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
Lee A, Ness R, Roman L, Terry K, Schildkraut J, Chang-Claude J, Doherty J, Menon U, Cramer D, Gayther S, Risch H, Gentry-Maharaj A, Goodman M, Modugno F, Eilber U, Moysich K, Berchuck A, Rossing M, Jensen A, Wicklund K, Cushing-Haugen K, Hogdall E, Rudolph A, Thompson P, Wilkens L, Kjaer S, Carney M, Stram D, Ramus S, Wu A, Pike M, Pearce C. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrical & Gynecological Survey 2016, 71: 470-471. DOI: 10.1097/01.ogx.0000489579.62561.b8.Peer-Reviewed Original ResearchThoracic Aortic Aneurysm from Chronic Antiestrogen Therapy
Tripathi R, Sainathan S, Ziganshin BA, Elefteriades JA. Thoracic Aortic Aneurysm from Chronic Antiestrogen Therapy. International Journal Of Angiology 2016, 26: 060-063. PMID: 28255218, PMCID: PMC5330750, DOI: 10.1055/s-0036-1583522.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply